[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 796 Introduced in House (IH)] 119th CONGRESS 1st Session H. R. 796 To amend the Federal Food, Drug, and Cosmetic Act to require a warning label advising that the effects of mifepristone can be counteracted, to amend the Public Health Service Act to establish a hotline to provide information to women seeking to counteract the effects of mifepristone, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES January 28, 2025 Mrs. Miller of Illinois (for herself, Mr. Babin, Mr. Moore of Alabama, Mr. Moore of West Virginia, Mr. Ogles, Mr. Webster of Florida, Ms. Tenney, Mr. Clyde, Mr. Harris of Maryland, and Mr. Weber of Texas) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To amend the Federal Food, Drug, and Cosmetic Act to require a warning label advising that the effects of mifepristone can be counteracted, to amend the Public Health Service Act to establish a hotline to provide information to women seeking to counteract the effects of mifepristone, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
HR 796 - 119
Introduced in House
Second Chance for Moms Act
3
Sections
0
Dollar amounts
1
Deadlines and effective dates
Jan 28, 2025
Text version date
Top statutory references
21 U.S.C. 352 1
42 U.S.C.
300 1
Deadline phrases
Effective date 1
Official source
Official PDF
Preview the source PDF from the official text formats without leaving this page, or open the original file in a new tab.
Structured text
Sec. 1.
SECTION 1. SHORT TITLE.
SECTION 1. SHORT TITLE. This Act may be cited as the ``Second Chance for Moms Act of 2025''.
Sec. 2.
SEC. 2. MIFEPRISTONE WARNING LABEL AND HOTLINE.
SEC. 2. MIFEPRISTONE WARNING LABEL AND HOTLINE. (a) Warning Label.-- (1) In general.--Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the following: ``(hh) If it is the drug mifepristone, and its labeling does not bear the following statement printed in conspicuous text: `WARNING: Medical evidence suggests that the abortifacient effects of mifepristone can be counteracted by natural progesterone, which can increase the chance of fetal survival. The American Society for Reproductive Medicine has determined that natural progesterone is safe in the first trimester of pregnancy. For more information, call [___].' (with the blank filled in to refer to the appropriate number for the hotline under section 1009 of the Public Health Service Act).''. (2) Effective date.--Section 502(hh) of the Federal Food, Drug, and Cosmetic Act (as added by paragraph (1)) applies beginning on the date that is 6 months after the date of enactment of this Act. (b) Hotline.--Title X of the Public Health Service Act (42 U.S.C. 300 et seq.) is amended by adding at the end the following: ``SEC. 1009. HOTLINE FOR REVERSAL OF EFFECTS OF MIFEPRISTONE. ``(a) In General.--The Secretary shall establish or maintain, directly or by grant or contract, a toll-free hotline to provide support for 24 hours a day, 7 days a week, for women seeking to reverse the effects of the drug mifepristone. ``(b) Referrals to APR Providers Only.--A referral through the hotline described in subsection (a) may only be made to a health care provider that provides abortion pill reversal services.''.
Cached official text analysis. This viewer uses cached official bill text and deterministic section, phrase, fiscal, agency, deadline, and statutory-reference extraction. The analysis is navigation support, not a legal interpretation; consult the official text for authoritative wording.
Sign in to use bill text research tools
Text find, signal filters, structured drilldowns, match navigation, and bill text bookmarks are account features. Create a free account to use them and return to this bill text.